Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology Pub Date : 2009-12-01

A Tomillero, M A Moral

{"title":"Gateways to clinical trials.","authors":"A Tomillero, M A Moral","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>[Methoxy-(11)C]PD-153035, 2-Methoxyestradiol; Adalimumab, Adecatumumab, Adefovir dipivoxil, ADH-1, ADX-10059, Aflibercept, AIR-human growth hormone, Aliskiren fumarate, AMG-221, Amlodipine besylate/olmesartan medoxomil, Aprepitant; Bavituximab, Bevacizumab, Bexarotene, BIBW-2992, BMS-690514, Bortezomib, Bosentan, Briakinumab; Capecitabine, Certolizumab pegol, Cetuximab, Cholecalciferol, Choline fenofibrate, Chorionic gonadotropin (human), Cixutumumab, Clopidogrel, CP-690550 citrate; Dabigatran, Dacetuzumab, Daclizumab, Dapagliflozin, Darbepoetin alfa, Dasatinib, Denosumab; Efavirenz, Elisidepsin, Enoxaparin, Enzastaurin hydrochloride, Eribulin mesilate, Erlotinib hydrochloride, Everolimus, Exenatide; Fenobam, Figitumumab, Filibuvir, Fondaparinux sodium, Fresolimumab; Gefitinib, Golimumab, Golnerminogene pradenovec; Ifosfamide, Imatinib mesylate, Ipilimumab, Ivabradine hydrochloride, Ixabepilone; Lapatinib ditosylate, Lenalidomide, Levocetirizine dihydrochloride, Liposomal vincristine, Liraglutide; M-118, Masitinib mesylate, Metformin hydrochloride, Micafungin sodium, Moxifloxacin hydrochloride; Neratinib; Oblimersen sodium, Ofatumumab, Olmesartan medoxomil; Paclitaxel nanoparticles, Palifosfamide lysine, Panobacumab, Panobinostat, Patupilone, Peginterferon alfa-2a, Pegylated arginine deiminase 20000, Piclozotan hydrochloride hydrate, Pixantrone maleate, Prasterone, Prasugrel, Prednisone, Progesterone, Prucalopride, pVGI.1 (VEGF-2); Retigabine, rhFSH, Rituximab, Rivaroxaban, Rosuvastatin calcium; Salinosporamide A, Selumetinib, Sipuleucel-T, Somatropin, Sorafenib, SSR-244738, Sunitinib malate; Tamoxifen citrate, Teduglutide, Telavancin hydrochloride, Telmisartan, Telmisartan/amlodipine, Telmisartan/hydrochlorothiazide, Temsirolimus, Tenofovir disoproxil fumarate, Tipifarnib, Tolvaptan, Trastuzumab, Trastuzumab-MCC-DM1, Travoprost, Tremelimumab; Valsartan/amlodipine besylate, Valsartan/amlodipine besylate/hydrochlorothiazide, Valsartan/hydrochlorothiazide, Vandetanib, Vorinostat.</p>","PeriodicalId":18443,"journal":{"name":"Methods and findings in experimental and clinical pharmacology","volume":"31 10","pages":"661-700"},"PeriodicalIF":0.0000,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Methods and findings in experimental and clinical pharmacology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

[Methoxy-(11)C]PD-153035, 2-Methoxyestradiol; Adalimumab, Adecatumumab, Adefovir dipivoxil, ADH-1, ADX-10059, Aflibercept, AIR-human growth hormone, Aliskiren fumarate, AMG-221, Amlodipine besylate/olmesartan medoxomil, Aprepitant; Bavituximab, Bevacizumab, Bexarotene, BIBW-2992, BMS-690514, Bortezomib, Bosentan, Briakinumab; Capecitabine, Certolizumab pegol, Cetuximab, Cholecalciferol, Choline fenofibrate, Chorionic gonadotropin (human), Cixutumumab, Clopidogrel, CP-690550 citrate; Dabigatran, Dacetuzumab, Daclizumab, Dapagliflozin, Darbepoetin alfa, Dasatinib, Denosumab; Efavirenz, Elisidepsin, Enoxaparin, Enzastaurin hydrochloride, Eribulin mesilate, Erlotinib hydrochloride, Everolimus, Exenatide; Fenobam, Figitumumab, Filibuvir, Fondaparinux sodium, Fresolimumab; Gefitinib, Golimumab, Golnerminogene pradenovec; Ifosfamide, Imatinib mesylate, Ipilimumab, Ivabradine hydrochloride, Ixabepilone; Lapatinib ditosylate, Lenalidomide, Levocetirizine dihydrochloride, Liposomal vincristine, Liraglutide; M-118, Masitinib mesylate, Metformin hydrochloride, Micafungin sodium, Moxifloxacin hydrochloride; Neratinib; Oblimersen sodium, Ofatumumab, Olmesartan medoxomil; Paclitaxel nanoparticles, Palifosfamide lysine, Panobacumab, Panobinostat, Patupilone, Peginterferon alfa-2a, Pegylated arginine deiminase 20000, Piclozotan hydrochloride hydrate, Pixantrone maleate, Prasterone, Prasugrel, Prednisone, Progesterone, Prucalopride, pVGI.1 (VEGF-2); Retigabine, rhFSH, Rituximab, Rivaroxaban, Rosuvastatin calcium; Salinosporamide A, Selumetinib, Sipuleucel-T, Somatropin, Sorafenib, SSR-244738, Sunitinib malate; Tamoxifen citrate, Teduglutide, Telavancin hydrochloride, Telmisartan, Telmisartan/amlodipine, Telmisartan/hydrochlorothiazide, Temsirolimus, Tenofovir disoproxil fumarate, Tipifarnib, Tolvaptan, Trastuzumab, Trastuzumab-MCC-DM1, Travoprost, Tremelimumab; Valsartan/amlodipine besylate, Valsartan/amlodipine besylate/hydrochlorothiazide, Valsartan/hydrochlorothiazide, Vandetanib, Vorinostat.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

通往临床试验的大门。

[甲氧基-（11）C]PD-153035，2-甲氧基雌二醇；阿达木单抗、阿卡图单抗、阿德福韦酯、ADH-1、ADX-10059、阿非利西普、AIR人生长激素、富马酸阿利吉仑、AMG-221、苯磺酸氨氯地平/奥美沙坦酯、阿普立坦；巴妥昔单抗、贝伐单抗、贝沙罗汀、BIBW-2992、BMS-690514、硼替佐米、波生坦、Briakinumab；卡培他滨、Certolizumab聚乙二醇、西妥昔单抗、胆钙化醇、非诺贝特胆碱、绒毛膜促性腺激素（人）、西须单抗、氯吡格雷、CP-690550柠檬酸盐；Dabigatran、Dacetuzumab、Dacalizumab、Dapaglilozin、Darbepoetin alfa、Dasatinib、Denosumab；依法韦仑、Elisidepsin、依诺肝素、盐酸恩扎斯他林、甲磺酸埃布林、盐酸埃洛替尼、依维莫司、艾塞那肽；Phenobam、Figitummab、Filibuvir、Fondaparinux钠、Fresolimumab；吉非替尼、Golimumab、Golnerminogene pradenovec；Ifosfamide、甲磺酸伊马替尼、Ipilimumab、盐酸依瓦拉定、Ixabepilone；二糖基拉帕替尼、来那度胺、盐酸左ocethyrine、脂质体长春新碱、利拉鲁肽；M-118、甲磺酸马西替尼、盐酸二甲双胍、米卡芬净钠、盐酸莫西沙星；耐拉替尼；奥必美生钠、奥法图单抗、奥美沙坦酯；紫杉醇纳米颗粒、帕利膦酰赖氨酸、帕诺巴单抗、帕诺比诺斯塔、帕图皮隆、聚乙二醇干扰素α-2a、聚乙二醇化精氨酸脱氨酶20000、盐酸吡唑坦水合物、马来酸皮克森特龙、普拉斯特龙、普拉格雷、泼尼松、孕酮、普鲁卡洛、pVGI.1（VEGF-2）；雷替加宾、rhFSH、利妥昔单抗、利伐沙班、瑞舒伐他汀钙；Salinosporamide A、Selumetinib、Sipuleucel-T、生长激素、索拉非尼、SSR-244738、舒尼替尼病；柠檬酸他莫昔芬、特杜古肽、盐酸Telavancin、替米沙坦、替米沙坦/氨氯地平、替米沙坦/氢氯噻嗪、特姆西莫司、富马酸替诺福韦二前列酯、替皮法尼、托伐普坦、曲妥珠单抗、曲妥妥珠单抗-MCC-DM1、Travoprost、Tremelimumab；缬沙坦/苯磺酸氨氯地平、缬沙坦/贝磺酸氨氯氯地平/氢氯噻嗪、缬沙坦-氢氯噻肼、Vandetanib、Vorinostat。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Methods and findings in experimental and clinical pharmacology 医学-药学

自引率

0.00%

发文量

审稿时长

>12 weeks